Intensive care.

TROG 12.01 was a randomized trial in Australia and New Zealand that, in the spirit of RTOG 1016, De-ESCALaTE and ARTSCAN, sought to determine if chemoradiation could be de-intensified for patients with low risk, HPV-mediated oropharyngeal cancer. Patients (n=189) received 70 Gy in 35 fractions with either weekly cisplatin or weekly cetuximab. There was no difference in the primary outcome of MD Anderson Symptom Inventory Severity Scale at 13 weeks. What was different? You guessed it, failure free survival was superior with weekly cisplatin (93% at 3 years) compared to weekly cetuximab (80%). In this trial, which notably included a lower risk population, there was no difference in overall survival. Ultimately, weekly cetuximab is inferior to weekly cisplatin for patients receiving definitive chemoradiation for OPC with no decrease in toxicity. | Rischin, Int J Radiat Oncol Biol Phys 2021